Effect Of Valsartan On Serum Adiponectin In Hypertensive Patients With Diabetes Mellitus

Background: studies have demonstrated that, according to the international diabetes related organizations and reliable statistics show, the number in the global scope of the diabetic patients in recent years is increasing rapidly, has reached 2810000000 people, while still taking a more astonishing growth rate increase year by year, China is a country with a large population in the world extremely large number, population, according to China's domestic Chinese medicine to the survey of 14 provinces and cities in China Diabetes Society, China's current diabetes patients over the age of 20 years the prevalence rate of 9.7%, the adult diabetic patients with a total number of 93000000. In addition, some British authoritative institutions for diabetes research results show, diabetic patients, 38% patients with hypertension complications. WHO related research results reported, hypertension is a common complication in patients with diabetes, the prevalence rate is about 30%, the patients with T2 DM and hypertension prevalence rate as high as 45%, in addition, higher than the UK's national 10%, China Diabetes Complicated with hypertension than that in non the prevalence of diabetes is more than 3 times. At the same time, according to the results of investigation on the chronic complications of diabetes CDS, hospital treatment in patients with diabetic complications in patients with cerebral vascular disease prevalence rate of the prevalence rate of 13% in the top three hospitals, hypertension prevalence rate of 40%, lower extremity vascular disease prevalence rate was 4%, the prevalence of cardiovascular disease is 19%, by the research above the results can be seen in patients with diabetes mellitus,hypertension is the most common and the highest incidence of complications.Objective: Diabetes and hypertension are two common diseases in clinic. In particular, the occurrence of hypertension combined with diabetes, the patient will be accelerated by the large artery atherosclerosis. High blood glucose, hypertension and atherosclerosis, not only have a common genetic, but also the existence of a certain biochemical and metabolic basis,based on the insulin resistance process, also is the key link in the pathophysiology of. The study shows that the serum adiponectin level in patients with hypertension and diabetes mellitus, and it is in a state of continuous reduction, while the high serum adiponectin levels not only have a beneficial effect on metabolic disorders, but also have a positive effect on cardiovascular disease. The purpose of this study was to observe the changes of serumadiponectin in patients with hypertension and diabetes mellitus, and to demonstrate the effect of valsartan on the treatment of hypertension and diabetes.Methods: Retrospective analysis of the clinical data of patients with hypertension combined with diabetes in our hospital outpatient department were randomly divided into two groups, that is, valsartan group and amlodipine group. Two groups of patients before treatment, the blood pressure and heart rate of two groups of patients were detected,valsartan group was treated with valsartan, amlodipine group was treated with amlodipine,the two groups were treated at least two months, two groups of patients with heart rate and blood pressure and lipid levels were reviewed.Results: The systolic and diastolic blood pressure and diastolic blood pressure after treatment were significantly lower than those before treatment, and the and P<0.05 were statistically significant. At the same time of valsartan in patients after Dewang serum adiponectin levels and treatment before, increased significantly, P < 0.05, with statistical significance. After treatment, the levels of blood glucose and insulin resistance and insulin resistance were significantly lower in patients treated with valsartan, compared with that before treatment, P<0.05, and it was statistically significant. There was no obvious change,P>0.05, no significant change, but it was comparable with that of the patients before and after treatment; In the aspect of CRP changes, comparation between groups, the Hs-CRP levels after treatment of the two groups of patients were significant lower than before treatment, P <0.05; Comparation within groups, the differences of Hs-CRP levels before and after treatment between the two groups were not significant, P> 0.05.Conclusion: The results of comparative analysis, the study found that the use of valsartan in patients with hypertension and diabetes mellitus, serum adiponectin levels in a lower state,while the high serum adiponectin level not only has a beneficial effect on metabolic disorders, but also has a positive effect on cardiovascular disease. To study the effect of valsartan on serum adiponectin in patients with hypertension and diabetes mellitus, and to provide a theoretical basis for future research. At the same time, valsartan can reduce the blood pressure of patients, not only increase the serum adiponectin level, but also improve the insulin resistance.